Experimental studies on signal transduction pathways in rheumatoid arthritis
Bijl-Westra, Johanna

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2005

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Strong inhibition of TNF-α production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor

Johanna Westra¹
Berber Doornbos-van der Meer¹
Peter de Boer³
Miek A van Leeuwen¹
Martin H van Rijswijk¹
Pieter C Limburg¹,²

From the Departments of ¹ Rheumatology, ² Pathology and Laboratory Medicine, University Medical Center Groningen, The Netherlands, and ³ Pharmaceutical Research and Development, Johnson and Johnson, Saunderton, United Kingdom

ABSTRACT
In inflammatory processes the p38 mitogen activated protein kinase (MAPK) signal transduction route regulates production and expression of cytokines and other inflammatory mediators. Tumor necrosis factor α (TNF-α) is a pivotal cytokine in rheumatoid arthritis (RA) and its production in macrophages is under control of the p38 MAPK route. Inhibition of the p38 MAPK route may inhibit production not only of TNF-α, but also of other inflammatory mediators produced by macrophages, and indirectly of inflammatory mediators by other cells induced by TNF-α stimulation. Here we investigate the effects of RWJ 67657, a p38 MAPK inhibitor, on mRNA expression and protein production of TNF-α and other inflammatory mediators, in monocyte-derived macrophages (MDM). A strong inhibition of TNF-α was seen at pharmacological relevant concentrations of RWJ 67657, but also inhibition of mRNA expression of IL-1β, IL-8 and COX-2 was shown. Furthermore, it was shown that monocyte-derived macrophages have a high constitutive production of MMP-9, which is not affected by p38 MAPK inhibition. The results presented here may have important implications for the treatment of rheumatoid arthritis.

Key words. COX-2, matrix metalloproteinase, monocyte-derived macrophage, p38 MAPK inhibitor, TNF-α
INTRODUCTION
Rheumatoid arthritis (RA) is characterized by chronic inflammation of synovial tissue and destruction of cartilage and bone in the joints \(^1\). Macrophages play an important role in RA, as the rheumatoid synovium is intensively infiltrated by macrophages and their numbers correlate with clinical scores \(^2\) and articular destruction in RA \(^3\). RA patients with active disease display a faster generation of CD14+ myelomonocytic cells from the bone marrow and faster differentiation into HLA-DR+ cells than control individuals do \(^4\). Activation of the monocytic lineage in inflammatory disease is not only restricted to synovial macrophages, but extends to circulating monocytes and other cells of the mononuclear phagocyte system \(^5\). The activation state of monocytes/macrophages is characterized by increased expression and transcription of interleukin-1\(\beta\) (IL-1\(\beta\)) and tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), but also of other pro-inflammatory and regulatory cytokines and growth factors \(^6\).

Highly specific therapeutics have been developed to target these cytokines, like monoclonal antibodies, soluble receptors, binding proteins, and receptor antagonists. TNF-\(\alpha\) blockade has been the major breakthrough in the therapy of RA during the past ten years. However more than half of the patients do not achieve adequate responses, remissions are rare and these drugs do have side effects \(^7\);\(^8\).

The importance of mitogen-activated protein kinases (MAPK) in cell biology has been reported in many studies concerning different inflammatory diseases. These MAPK belong to three families: the extracellular signal regulated kinases (ERK), the c-Jun N-terminal or stress activated protein kinases (JNK/SAPK) and the p38 MAPK. All three families have been shown to become activated in macrophages using a variety of stimuli both in primary cells and in cell lines \(^9\). In the RA synovium p38 MAPK is predominantly activated in endothelial cells and in the lining layer \(^10\). Inhibition of p38 MAPK therefore could provide an interesting target for intervention in inflammation as it occurs in the synovia in rheumatoid arthritis.

In vitro stimulation of macrophages with LPS (lipopolysaccharide) leads to activation of MAPK cascades through the LPS receptor (CD14) or Toll-like receptors \(^9\). The ability of bacterial toxins or super-antigens to induce pro-inflammatory responses leading to the production of TNF-\(\alpha\) and IL-1 is relevant in view of the possible micro-organism aetiology in RA \(^11\). Stimulation of monocytes with LPS induces a number of matrix metalloproteinases (MMPs), including two prominent monocytic MMPs: interstitial collagenase (MMP-1) and gelatinase-B (MMP-9). These enzymes are involved in the connective-tissue loss associated with chronic inflammatory diseases. In vivo a significant part of macrophage effector responses occur through cell-contact dependent signalling with several inflammatory cells, mainly T-cells and fibroblasts. A few soluble stimuli are known to have a stimulatory effect on macrophages, like IL-15 and IL-17. It has also been reported that IL-17 induces the production of MMP-9 and cyclo-oxygenase-2 (COX-2, which is the rate-limiting enzyme in prostaglandin and leukotriene synthesis) in monocytes/macrophages \(^12\).

The p38 MAPK inhibitor RWJ 67657 (4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol) has been shown to inhibit the release of TNF\(\alpha\) from LPS-treated human peripheral blood mononuclear cells with an IC\(_{50}\) of 3 nM \(^13\). Moreover this compound effectively inhibited endotoxin-induced clinical effects and cytokine release in normal healthy volunteers \(^14\). Furthermore a report was
published in which pharmacokinetics and pharmacodynamics of RWJ 67657 were presented, showing that the compound has acceptable safety to warrant further investigation 15. Our group recently showed that RWJ 67657 significantly inhibited IL-6, IL-8, MMP-3 and COX-2 mRNA expressed by IL-1β and/or TNF-α stimulated rheumatoid synovial fibroblasts 16.

It has been shown that differences occur in signalling pathways in myeloid cells in relation to the maturation stage of macrophages 17. Strong inhibition of TNF-α in monocytes has been reported due to p38 MAPK inhibition 13, but the effects in matured macrophages are not fully known. Therefore in this study we investigated the effects of the p38 MAPK inhibitor RWJ 67657 on the mRNA expression and production of inflammatory cytokines and MMPs by stimulated monocyte-derived macrophages (MDM). We investigated macrophages, differentiated in medium with pooled serum or by the method described by Plesner and co-workers 18 and compared MDMs from healthy controls and rheumatoid arthritis patients. Strong inhibition of mRNA expression and production of TNF-α by RWJ 67657 was found, as well as inhibition of IL-1β, IL-8 and COX-2 mRNA expression.

**MATERIALS AND METHODS**

**Reagents**

RWJ 67657 was provided by Johnson and Johnson (R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey, USA). Antibodies for flowcytometry were obtained from IQProducts, Groningen, The Netherlands. Lipopolysaccharide was purchased from Sigma-Aldrich ( Zwijndrecht, The Netherlands). Recombinant human macrophage colony stimulating factor (M-CSF) and ELISA antibodies were from R&D Systems (Minneapolis, Minnesota, USA). Foetal calf serum (FCS) and RPMI 1640 culture medium were obtained from Biowhittaker (Verviers, Belgium). All reagents for RNA isolation and reverse transcriptase reaction were purchased from Invitrogen, Life Technologies (Gaithersburg, Maryland, USA). Reagents for real-time RT-PCR were obtained from Applied Biosystems (Foster City, California, USA). Specific antibodies to p38 MAPK, phospho-p38 MAPK and phospho-MAPKAPK-2 were purchased from Cell Signalling Technologies (Beverly, Massachusetts, USA) and detecting antibody peroxidase-swine-anti-rabbit was from DAKO (Glostrup, Denmark).

**Macrophage culture**

Blood was obtained from RA patients who had given informed consent, and from healthy laboratory workers. Peripheral mononuclear cells were isolated by Lymphoprep density gradient centrifugation from citrated blood. Cells were suspended in RPMI with gentamycin at 10⁶ cells/ml and seeded in 6-well plates (Costar, Badhoevedorp, The Netherlands) in 3 ml or 0.5 ml in 24-well plates and cultured at 37°C in a 5% CO₂ atmosphere. After 2 hours non-adherent cells were discarded and adherent monocytes were allowed to differentiate into macrophages in RPMI containing gentamycin, 50 ng/ml M-CSF + 1% FCS 18, while medium was refreshed at day 2. To compare methods monocytes were also differentiated in RPMI with gentamycin + 2% pooled human serum; on day 2 and 5 fresh medium was added to the wells. Cells were cultured for 5 or 7 days. We found no marked differences between

48
differentiation methods and decided to perform further experiments with macrophages differentiated with M-CSF and FCS.

**Flowcytometric analysis**
Expression of surface markers CD14 (LPS receptor), HLA-DR, CD18 (β2 integrin subunit), CD36 (GPIIIb, GPIV) and CD83 (dendritic cell marker) on monocytes in the PBMC-fraction and on differentiated macrophages was detected by flowcytometric analysis in an Epics-Elite Flowcytometer (Coulter Electronics, Mijdrecht, The Netherlands).

**Phosphorylation studies**
Phosphorylation of p38 MAPK in MDM was analyzed by western blotting. Cells were cultured in RPMI containing gentamycin, 50 ng/ml M-CSF + 1% FCS for 5 days and stimulated with 50 ng/ml LPS for various periods of time. Cell extracts were prepared by lysing the cells with 1x SDS sample buffer (containing 2% SDS, 10% glycerol, 50 mM dithiothreitol, 62.5 mM Tris-HCl (pH=6.8) and 0.01% brome-phenol blue). Cells were scraped off the wells and the lysates were subsequently sonicated for 5-10 seconds and boiled for 5 minutes. After centrifugation the samples were loaded onto a 10% SDS-PAGE gel and resolved by running at 200 V and 15 Watt constant. Semidry-blotting was performed onto nitrocellulose membrane and immunodetection was with anti-phospho-p38 MAPK and peroxidase-anti-rabbit-immnoglobulins. Enhanced chemiluminescence (ECL) detection was performed according to the manufacturers guidelines (Lumi-Lightplus, Roche Diagnostics, Mannheim, Germany).
To determine the effect of RWJ 67657 on phosphorylation of p38 MAPK and its downstream substrate MAPK-activating protein kinase-2 (MAPKAPK-2) a concentration range of the p38 MAPK inhibitor (0, 0.01, 0.1, 1, 10 µM) was added 1 hour before stimulation with 50 ng/ml LPS for 30 minutes. Blotting experiments were performed with specific antibodies to p38 MAPK, phospho-p38 MAPK, and phospho-MAPKAPK-2.

**Determination of TNF-α, IL-1β, IL-6, IL-8, MMP-1, MMP-9 and TIMP-1 levels in cell culture supernatants**
MDM from 8 healthy controls and 9 RA patients, who were not treated with steroids, were cultured in 24 well-plates in RPMI containing gentamycin, 50 ng/ml M-CSF + 1% FCS for 5 days. The cells were subsequently pre-treated with increasing concentrations of RWJ 67657 (stocksolution 10 mM in dimethylsulfoxide [DMSO]), from 0.01 µM -10 µM for 1 hour prior to stimulation with 50 ng/ml LPS for 24 hours. Cytokine (TNFα, IL-1β, IL-6 and IL-8), MMP-1, MMP-9 and tissue inhibitor of matrix metalloproteinases (TIMP)-1 levels were measured in cell supernatants by ELISA, using matched antibody pairs for ELISA and recombinant proteins as standards from R&D Systems. Detection limits for all cytokine ELISAs was 20 pg/ml. For optimal determination of MMP-1, MMP-9 and TIMP-1 96 well plates (Greiner M129A) were precoated with F(ab)2 fragments of goat-anti-mouse IgG-Fc (Jackson, West Grove, Pennsylvania, USA) in 0.1M carbonate buffer (pH=9.6) for at least 48 hours before coating of the capture antibody. After sample incubation and binding of the biotinylated detection antibodies, the color reaction was performed with
streptavidin-poly-HRP (Sanquin, Amsterdam, The Netherlands) and tetramethyl-
benzidin (TMB, Roth, Karlsruhe, Germany). The detection limit for MMP-1 and
TIMP-1 was 1 ng/ml and for MMP-9, 0.1 ng/ml.

**RNA isolation and real-time RT-PCR**

Monocyte-derived macrophages from healthy controls were cultured in 6 well-plates
in RPMI containing gentamycin, 50 ng/ml M-CSF + 1% FCS for 5 days. First
macrophages were stimulated with 50 ng/ml LPS for different periods of time to
determine optimal mRNA expression of TNF-α, IL-1β, IL-6, IL-8, MMP-9 and COX-
2 genes. At the optimal time point the effect of p38 MAPK inhibition on LPS-
stimulated MDM was determined by pre-treatment of the cells with increasing
concentrations of RWJ 67657 for 1 hour. Total RNA was isolated from the cells with
TRIzol reagent according to the manufacturers instructions (Life Technologies). After
DNase treatment (Ambion DNA-free, Austin, Texas, USA) cDNA was synthesized
from 1.0 µg of total RNA using M-MLV Reverse Transcriptase and oligo (dT)$_{24}$ (Life
Technologies).

For detection of mRNA expression a fluorescence based real-time RT-PCR was
performed, which allows relative quantification of steady-state mRNA. The amount of
emitted fluorescence is proportional to the amount of PCR product and enables the
monitoring of the PCR reaction. For the measurement of IL-1β, TNF-α, IL-6, IL-8,
MMP-9, COX-2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 1µl of
cDNA in triplicate was used for amplification by the real-time quantitative PCR
system (ABI Prism 7900HT Sequence Detection System, Applied Biosystems) with
specific Taqman primers/probes. The Assay-on-Demand numbers for the genes were:
IL-1β: Hs00174097_m1, TNFα: Hs00174128_m1, IL-6: Hs00174131_m1, IL-8:
Hs00174103_m1, MMP-9: Hs00234579_m1, COX-2: Hs00153133_m1, and GAPDH:
Hs009999905_m1.

The amount of target, normalized to an endogenous reference (GAPDH) and relative
to a control sample, is given by: $2^{-\Delta\Delta CT}$ in which $C_T$ is the threshold cycle. The results
are expressed as fold induction relative to untreated samples.

**STATISTICS**

Paired T-tests were performed using GraphPad Prism version 3.00 for Windows,
GraphPad Software (San Diego, CA, USA).

**RESULTS**

**Macrophage differentiation**

Expression of surface markers on monocytes and macrophages was measured by
flowcytometry. In figure 1 the mean fluorescence intensity (MFI) of CD14 and HLA-
DR on monocytes (left panel) and macrophages differentiated in 50 ng/ml M-CSF and
1% FCS after 5 days (right panel) is shown, the number of cells measured in the
flowcytometer. Macrophages differentiated in this way showed lower expression of
CD14 compared to monocytes relative to the isotype control, whereas the HLA-DR
expression did not differ between both cell types.
Expression of CD18 increased with differentiation, while expression of CD36 decreased (data not shown). Expression of CD83 was not seen on matured macrophages, excluding differentiation into dendritic cells. For further experiments monocytes differentiated in medium with 50 ng/ml M-CSF and 1% FCS for 5 days were used.

Effect of RWJ 67657 on phosphorylation of p38 MAPK and MAPKAPK-2
In figure 2A a representative example is shown of phosphorylation of p38 MAPK in MDMs after stimulation with 50 ng/ml LPS. Phosphorylation occurs already after 15 minutes, is maximal at 30-60 minutes and diminishes after 2 hours. p38 MAPK is constitutively expressed in the cells as is demonstrated in the control blot. The effect of RWJ 67657 on phosphorylation of p38 MAPK and its direct downstream substrate MAPKAPK-2 measured after 30 minutes of stimulation with 50 ng/ml LPS is shown in figure 2B. RWJ 67657 does not inhibit phosphorylation of p38 MAPK, but does inhibit its activity, as can be seen from the strong inhibition at 0.01 \( \mu \)M and the complete inhibition of MAPKAPK-2 phosphorylation at 0.1 \( \mu \)M RWJ 67657. The solvent, 0.1% DMSO, did not affect phosphorylation of either kinase.

Effect of RWJ 67657 on cytokine and MMP production
Stimulation of MDM with 50 ng/ml LPS for 24 hours resulted in increased production of TNF-\( \alpha \), IL-6, IL-8 and MMP-9 both in control macrophages and in rheumatoid arthritis macrophages (figure 3A). Production of IL-1\( \beta \), MMP-1 and TIMP-1 was too low for detection. Before stimulation, TNF-\( \alpha \) production was below detection limit, while after stimulation the mean production in control MDM was 2.204 (± 1.993) ng/ml and in RA-MDM 2.150 (± 1.816) ng/ml.
Pre-treatment of the macrophages with increasing concentrations of RWJ 67657 showed a dose-dependent decrease of protein production for TNF-α and IL-8. Inhibition of TNFα production was seen with an IC₅₀ of 0.015 µM for control cells and 0.03 µM for RA cells (figure 3B). For IL-8 production the IC₅₀ was 0.3 µM for control cells and 1.2 µM for RA cells. IL-6 and MMP-9 production was inhibited only at concentrations between 1 and 10 µM RWJ 67657. Pre-treatment of MDMs with 0.1% DMSO had no significant effect on protein production (data not shown).

**Effects of RWJ 67657 on mRNA expression**

To determine optimal stimulation time points for the genes involved in this study MDM of 2 healthy controls were stimulated during 0.5, 2, 4, 8, 12, and 24 hours with 50 ng/ml LPS. mRNA expression of TNF-α, IL-1β, IL-6, IL-8 and COX-2 was measured with real-time RT-PCR as depicted in figure 4. A significant increase of mRNA expression of all but MMP-9 was found after stimulation with LPS. After 4 and 8 hours of stimulation most genes were highly expressed, IL-8 mRNA expression was still increased after 12 and 24 hours. For measurement of the effects of the p38 MAPK inhibitor MDMs were stimulated for 4 hours.
Figure 3. Protein production of tumor necrosis factor (TNF)-α, IL-6, IL-8 and matrix metalloproteinase-9 (MMP-9) by monocyte-derived macrophages from healthy controls (n=8, open squares) and rheumatoid arthritis patients (n=9, filled squares). Cells were stimulated with LPS for 24 hours and treated one hour beforehand with RWJ 67657 at various concentrations. Protein production was measured in supernatants by ELISA and expressed in ng/ml (A). Inhibition was calculated against the stimulated control and depicted in figure B. Bars show mean and SEM. (* p<0.05, ** p<0.001, paired T-test, calculated against the stimulated control). Unst = unstimulated.
Figure 4. Time course of induction of mRNA expression of tumor necrosis factor (TNF)-α, IL-1β, IL-6, IL-8 and cyclo-oxygenase-2 (COX-2).

Monocyte-derived macrophages from healthy controls (n=2) were stimulated for increasing periods of time with lipopolysaccharide (50 ng/ml). mRNA expression was determined with real-time RT-PCR and results were calculated as fold induction in comparison to unstimulated cells (fold induction=1).

As can been seen in figure 5 there is a dose-dependent decrease in mRNA expression with increasing RWJ 67657 concentration. TNF-α mRNA expression is inhibited by 48.4% at 0.01 µM and 65.8% at 0.1 µM p38 MAPK inhibitor. IL-1β, IL-8 and COX-2 mRNA expression was reduced by 40.2%, 56.6% and 65.0% respectively at 1 µM. MMP-9 mRNA expression is not induced and not inhibited and proved to be constitutively expressed at a high level. Control incubations with 0.1% DMSO had no significant effect on mRNA expression, as can been seen in figure 5.

DISCUSSION

In this study we have shown the significant inhibition of TNF-α production in MDMs by the p38 MAPK inhibitor RWJ 67657. The strong inhibition was seen both at the level of mRNA expression and protein production, so inhibition is already apparent at the level of transcription.

p38 MAPK activity in RA is found predominantly in the synovial lining layer and in endothelial cells in the synovium. The lining layer consists mainly of fibroblasts and macrophages, both important players in the process of inflammation by the production of cytokines and degrading enzymes. Recently our group demonstrated strong inhibition of IL-6, IL-8, COX-2 and MMP-3 expression in rheumatoid synovial fibroblasts by the p38 MAPK inhibitor RWJ 67657. Studying macrophages in vitro raises some difficulties, because isolation and culture of macrophages from synovial tissue is disturbed by the overgrowth of fibroblasts. Therefore, macrophages differentiated from peripheral blood monocytes are widely used for in vitro studies. By
Figure 5. mRNA expression of tumor necrosis factor (TNF-α), IL-1β, cyclo-oxygenase-2 (COX-2), IL-6, IL-8 and matrix metalloproteinase-9 (MMP-9) of monocyte-derived macrophages from healthy controls (n=5). Cells were stimulated with LPS for 4 hours and pre-treated with a concentration range of RWJ 67657. mRNA expression was determined with real-time RT-PCR and results were expressed as fold induction compared to unstimulated cells (fold induction=1). Bars show means and SEM (* p<0.05, paired T-test, calculated against the stimulated control)

using M-CSF and low FCS concentrations macrophages were generated, with high HLA-DR expression, that were not activated 18. Current treatment strategies in RA, including TNF-α and IL-1 blocking agents, alone or in combination with, for example methotrexate, still have limited efficacy in a substantial proportion of patients. Recently, Redlich and co-workers reviewed the multiple pathogenesis pathways involved in RA, and the possible targets for therapies, and stressed the importance of aiming at the interference of both with the pathways leading to inflammation and with those ultimately leading to destruction 8. Inhibition of signal transduction cascades may fit in this concept, because they are involved in the activation of pro-inflammatory cytokines as well as of MMP genes.

The p38 MAPK inhibitor RWJ 67657 has been reported to be specific for p38 α and β, and has no activity for other kinases 13. A first-in-human study investigating the pharmacokinetics and pharmacodynamics of RWJ 67657 demonstrated that a single
oral intake of 0.25 ranging up to 30 mg/kg resulted in plasma levels of 0.01 µM to 6 µM \(^1\). Furthermore the study showed that at the doses tested there were no significant adverse effects.

p38 MAPK acts mainly through phosphorylation of its down-stream substrate MAPKAPK-2 and a variety of transcription factors \(^2\). Mice that lack MAPKAPK-2 show increased stress resistance and survive LPS-induced endotoxic shock, due to a reduction of 90% in the production of TNF-α \(^3\). The level and stability of TNF-α mRNA was not reduced in these mice, so the inhibition was at the post-transcriptional level. With western blotting we demonstrated complete inhibition of phosphorylation of MAPKAPK-2 at 0.1 µM RWJ 67657, and strong inhibition at 0.01 µM. In our study TNFα production was significantly inhibited at nanomolar concentrations RWJ 67657, and mRNA expression was also decreased, by nearly 50% at 10 nM. Inhibition of p38 MAPK activity leads to reduced TNF-α mRNA expression and therefore reduced TNFα production, while inhibition of MAPKAPK-2, as in MAPKAPK-2 knock-out mice, leads to reduced TNF-α production without affecting the mRNA levels.

IL-6 production and mRNA expression were not inhibited by p38 MAPK inhibition, but IL-8 production and mRNA expression were inhibited for more than 50% at 1 µM RWJ 67657. Bhattacharyya and co-workers showed that LPS from Helicobacter pylori stimulates IL-8 release from cells of the monocytic lineage through activation of NF-κB and MAPK cascades \(^4\), and we demonstrated that in MDM the p38 MAPK route plays an important role in this process.

Already in 1992 Herzyk and co-workers published findings showing that macrophage and monocyte IL-1β regulation differs at multiple sites \(^5\). Macrophages did not differ from monocytes in LPS sensitivity but had limitations in IL-1β release. Our study shows mRNA expression of IL-1β in MDM, as well as a reduction of mRNA expression at 1 µM RWJ 67657, but protein production in MDMs was below the detection limit of the measurement.

We found a reduction of 65% in COX-2 mRNA expression after treatment with 1 µM RWJ 67657. It was previously demonstrated that p38 MAPK plays a role in transcription and stabilisation of COX-2 mRNA \(^6\). However, Caivano and Cohen showed that both p38 MAPK and ERK influence COX-2 mRNA expression through activation of mitogen- and stress-activated protein kinase-1 (MSK-1) \(^7\), an activator of important transcription factors like ATF-2 and CREB. Our results indicate an important role for p38 MAPK in COX-2 mRNA expression in MDM.

In synovial tissue, the presence of macrophages is often seen together with the expression of MMPs and TIMP-1 \(^8\). In our study MMP-1 and TIMP-1 could not be detected in the cell supernatants of MDMs after LPS stimulation, in contrast to high production of MMP-9. MMP-9 is associated with macrophages and peripheral blood mononuclear cells and has a broad substrate specificity and may contribute together with collagenases to the degradation of fibrillar collagens, basement membrane-components and stromal ECM molecules \(^9\). Stimulation with LPS induced a two-fold induction of MMP-9 levels, which could not be inhibited by pretreatment with RWJ 67657 at low concentrations. Also, mRNA expression of MMP-9 could not be induced by LPS stimulation, and no inhibition by p38 MAPK inhibitor was observed. This latter finding is in accordance with the study by Lai and co-workers, which showed...
that LPS induction of MMP-9 in monocytes is mainly regulated by the ERK1/2 pathway and not the p38 MAPK pathway. 

p38 MAPK inhibitors have effects on different cell types, thereby possibly enhancing the therapeutic effects, but increasing the risk of side effects. One of the reasons for undesirable effects might be the cross-reactivity against other kinases, which was not the case for RWJ 67657. The preliminary pharmacokinetic data suggest a twice-daily dosing regimen, while our data show significant effects at low concentrations.

CONCLUSIONS
A significant inhibition of TNF-α production and mRNA expression in LPS-stimulated monocyte-derived macrophages was observed after pre-treatment with RWJ 67657, a p38 MAPK inhibitor at pharmacological relevant concentrations. Inhibition of mRNA expression of IL-1β, IL-8 and COX-2 was also detected. MMP-9 was found to be constitutively produced at high levels and not inhibited by RWJ 67657. The results presented here could have important implications for the treatment of RA, since the drug used in this study has already proven to be safe in an in-human study. More research upon the effects of p38 MAPK inhibition on other cell types involved in inflammation will establish its applicability as a drug in the near future.

ACKNOWLEDGEMENTS
This work was supported by the Dutch Rheumatology Foundation and Johnson and Johnson Pharmaceutical Research and Development, Raritan, New Jersey, USA.

REFERENCES